MRK
Merck (MRK)
NYSE
$144.85-$2.91 (-1.97%)
Price as of Nov 16, 2026 7:38 PM EST
  • $364.3B
    Market Cap
  • 63.69%
    1-Year Change
  • Drug Manufacturers - General
    Industry

Key Performance

More
  • Earnings Score: 44
  • Momentum Score: 67
  • True Yield: 41
  • Financial Health Score: 8
TradeSmith Loading

Latest Research & News

Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe.

Gilead Sciences increased its quarterly dividend by 3.8% to $0.82, marking the 11th consecutive year of dividend increases. The company's strong HIV franchise generated 18% higher sales year-over-year, while its oncology expansion shows promise with Trodelvy reporting 42% sales growth. With a low payout ratio of 29.8%, Gilead has ample room to sustain dividend growth and fund $32 billion in research projects through 2030.

11/05/2026, 5:45 AM • The Motley Fool

History Says This ETF Is a Fantastic Buy-and-Hold Investment -- and It Could Turn $100 per Month Into $359,492

The Schwab U.S. Dividend Equity ETF (SCHD) is highlighted as a strong buy-and-hold investment with a 15-year annualized return of 13.11%. The article suggests that $100 monthly investments could grow to $359,492 over 30 years. SCHD offers diversification away from AI stocks with holdings in energy, healthcare, and consumer staples sectors, making it potentially attractive for investors concerned about tech stock volatility.

11/04/2026, 5:30 PM • The Motley Fool

Medicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders

Medicenna Therapeutics has completed enrollment of 152 patients in its Phase 1/2 ABILITY-1 study evaluating MDNA11, a long-acting IL-2 Superkine for cancer treatment, both as monotherapy and in combination with Merck's pembrolizumab. Updated data will be presented at SITC 2026 on November 7th, with a key opinion leaders webinar scheduled for November 10th. Previous results showed objective response rates of 36% for MDNA11 monotherapy and 43% in combination with pembrolizumab.

11/04/2026, 7:00 AM • GlobeNewswire

Could Investing in Moderna's Stock Double Your Money?

Moderna's stock has surged over 650% in 2026 driven by excitement around its cancer vaccine intismeran, developed with Merck. While the vaccine shows promising clinical trial results for melanoma and is being evaluated for other cancers, it remains unapproved. Despite this year's gains, the stock is still down 36% over five years. For the stock to double to a $180 billion valuation, Moderna would need strong revenue generation beyond expectations, making it a high-risk investment.

11/03/2026, 5:08 AM • The Motley Fool

Merck to Divest CDMO Business to Lonza

Merck has signed a definitive agreement to divest its contract development and manufacturing organization (CDMO) business to Lonza for a mid-triple-digit million-euro amount. The transaction, expected to close in mid-2027, allows Merck to focus on innovation-driven businesses while positioning the CDMO business for growth under Lonza's dedicated platform. The deal includes Merck's CDMO operations across multiple US sites in California, Wisconsin, Missouri, and Indiana.

11/03/2026, 1:45 AM • GlobeNewswire

BTK Inhibitors Market to Expand During the Forecast Period (2026–2036) as Targeted Treatments Advance Across B-Cell Malignancies and Autoimmune Disorders | DelveInsight

The BTK inhibitors market is expected to experience steady growth through 2036, driven by increasing prevalence of B-cell malignancies, established clinical benefits, and an expanding pipeline of next-generation therapies. Key developments include FDA approvals for new indications and multiple drugs in clinical trials targeting oncology and autoimmune diseases across the 7MM markets.

11/02/2026, 1:00 PM • GlobeNewswire

If Moderna's CEO Is Right, the Stock's Rally Could Just Be Getting Started

Moderna's stock has surged 650% in 2026, driven by excitement around its cancer vaccine intismeran developed with Merck. Recent trials showed the vaccine reduced melanoma death/recurrence risk by 42% when combined with Merck's Keytruda. CEO Stéphane Bancel believes intismeran could work across multiple cancer types where Keytruda is effective, potentially unlocking significant growth. However, the stock faces sky-high expectations and intismeran remains unapproved, warranting cautious investor approach.

11/02/2026, 9:19 AM • The Motley Fool

Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs

GLP-1 drugs like Ozempic, Wegovy, and Mounjaro are revolutionizing healthcare with massive growth potential. Beyond weight loss and diabetes, research shows these drugs may treat cardiovascular, kidney, liver, and other diseases, with emerging evidence of anti-aging benefits. Morgan Stanley forecasts the obesity drug market will reach $190 billion by 2035, but the author believes this is understated given untapped international markets and expanding use cases.

11/02/2026, 9:00 AM • The Motley Fool

Why Merck Stock Flew Higher on Friday

Merck's stock rose 2.18% on Friday following strong Q3 2026 earnings results that beat analyst expectations. The company reported 5% sales growth to over $18 billion, driven by its blockbuster cancer drug Keytruda, and adjusted net income of $6.2 billion. Multiple analysts raised their price targets on the stock, with Bank of America Securities raising its target to $165 and JPMorgan Chase raising theirs to $175, both maintaining buy recommendations.

10/30/2026, 7:58 PM • The Motley Fool

Could Revolution Medicines Be a Millionaire-Maker Stock?

Revolution Medicines (RVMD) has surged over 9x in three years following FDA approval of its cancer drug Rasonque for pancreatic cancer treatment. While the stock has delivered impressive returns, analysts suggest it's unlikely to reach the $1.6 trillion market cap needed to turn a $25,000 investment into $1 million. However, with additional pipeline candidates and analyst support, the company could still generate market-beating returns for long-term investors.

10/29/2026, 4:44 AM • The Motley Fool

Will Moderna Soar on Nov. 6?

Moderna stock has surged over 100% this year, driven by positive results from its personalized cancer vaccine candidate in combination with Merck's Keytruda. The company is scheduled to report Q3 earnings on Nov. 6, with investors focused on oncology progress and cancer vaccine development. While recent data leak caused a stock dip, the author expects the next major catalyst to come from fresh cancer vaccine data rather than the earnings report itself.

10/29/2026, 4:10 AM • The Motley Fool

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?

The article compares Amgen and Novo Nordisk as investment options for 2026. Amgen shows stronger revenue growth (9.9%) with a diversified portfolio across oncology and rare diseases, while Novo Nordisk boasts higher profitability (33.1% net margin) but faces pricing pressures and competition in the GLP-1 market. The author recommends Amgen for 2026 due to its consistent revenue growth and scale advantages, despite Novo Nordisk's cheaper valuation multiples.

10/27/2026, 10:50 AM • The Motley Fool

Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH?

The iShares U.S. Pharmaceuticals ETF (IHE) has outperformed VanEck Pharmaceutical ETF (PPH) over the past year, driven by concentrated exposure to Eli Lilly's GLP-1 drugs, delivering 38.2% returns versus PPH's 26.4%. However, PPH offers global diversification with European pharma giants, a higher dividend yield of 1.9%, and nearly identical expense ratios. IHE suits investors seeking recent momentum, while PPH appeals to those prioritizing international exposure and income.

10/26/2026, 11:40 AM • The Motley Fool

Breakfast News: Science Strikes Back at Cancer

Cancer treatment breakthroughs dominate ESMO 2026 conference with multiple drugs showing significant survival gains. U.S. stocks declined amid AI spending concerns and rising oil prices, with the Fed expected to hold rates steady Wednesday. Several Motley Fool-recommended companies report earnings this week including Alphabet, Amazon, and Mastercard. TransDigm's stock decline reflects valuation compression rather than business deterioration.

10/26/2026, 7:30 AM • The Motley Fool

Microbiotica Presents Phase 1b Clinical Data on MB097 at the European Society for Medical Oncology (ESMO) Congress 2026

Microbiotica announced positive Phase 1b MELODY-1 trial results for MB097, a precision microbiome therapeutic combined with pembrolizumab for advanced melanoma patients resistant to anti-PD-1 therapy. The treatment demonstrated safety, robust bacterial engraftment, and encouraging clinical responses with 14% objective response rate in the vancomycin-preconditioning arm, including deep tumor regressions.

10/26/2026, 3:00 AM • GlobeNewswire

Peers

Statistics

More
Day Range
$145.24
$147.99
$147.76
1-Year Range
$92.86
$156.45
$147.76
Latest Close$147.76
Change
+$0.81 (+0.55%)
Volume6,507,620
Market Cap$364.3B
Shares Outstanding2.5B
P/E (TTM)149.18
Diluted EPS (TTM)$0.99
Enterprise Value$408.5B

Information as of 11/13/2026

Company Profile

MERCK & CO INC
MERCK & CO INC
https://www.merck.com
$364.3B
Market Cap
$2.5B
Net Income
Sector: Healthcare
Industry: Drug Manufacturers - General
126 East Lincoln Avenue, Rahway, NJ, United States, 07065
908 740 4000

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Key Executives

  • Robert Davis
  • Dean Y. Li
  • Caroline Litchfield
  • Betty D. Larson
  • Jennifer L. Zachary

Current Ownership Distribution

  • Institutions37.6B (76.93%)
  • Mutual Funds11.3B (23.05%)
  • Insiders5.6M (0.01%)
  • Other0 (0.00%)